IBRX

IMMUNITYBIO, INC.

IBRX · CIK 1326110 · Annual (10-K) · Last 8 years

Financial Trends

Revenue$113M
20182025
Net Income−$351M
20182025
Operating CF−$305M
20182025
Free Cash Flow−$309M
20182025

Income Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Revenue$0.1B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B$0.0B
Cost of Revenue$0.0B$0.0B——————
Gross Profit————————
R&D Expense—$0.2B$0.2B$0.2B$0.2B$0.1B$0.0B$0.1B
SG&A Expense—$0.2B$0.1B$0.1B$0.1B$0.0B$0.0B$0.0B
Operating Income$-0.3B$-0.3B$-0.4B$-0.4B$-0.3B$-0.0B$-0.0B$-0.0B
Net Income$-0.4B$-0.4B$-0.6B$-0.4B$-0.3B$-0.0B$-0.0B$-0.0B
EPS (Basic)$-0.38$-0.59$-1.15$-1.04$-0.89———
EPS (Diluted)$-0.38$-0.62$-1.15$-1.04$-0.89———

Balance Sheet

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Total Assets$0.5B$0.4B$0.5B$0.4B$0.5B$0.2B$0.1B$0.2B
Current Assets$0.3B$0.2B$0.3B$0.1B$0.3B$0.1B$0.1B$0.1B
Cash & Equivalents$0.1B$0.1B$0.3B$0.1B$0.2B$0.0B$0.0B$0.0B
Total Liabilities$1.0B$0.9B$1.1B$0.8B$0.7B$0.0B$0.0B$0.0B
Current Liabilities$0.1B$0.1B$0.1B$0.5B$0.4B$0.0B$0.0B$0.0B
Stockholders' Equity$-0.5B$-0.5B$-0.6B$-0.4B$-0.2B$0.1B$0.1B$0.1B

Cash Flow Statement

MetricFY 2025↕FY 2024↕FY 2023↕FY 2022↕FY 2021↕FY 2020↕FY 2019↕FY 2018↕
Operating Cash Flow$-0.3B$-0.4B$-0.4B$-0.3B$-0.3B$-0.1B$-0.1B$-0.1B
Investing Cash Flow$-0.1B$-0.0B$-0.0B$0.0B$-0.1B$-0.0B$0.0B$0.1B
Capital Expenditures$0.0B$0.0B$0.0B$0.1B$0.0B$0.0B$0.0B$0.0B
Financing Cash Flow$0.4B$0.3B$0.6B$0.2B$0.5B$0.1B$0.0B$-0.0B
← Companies